Ranibizumab for Choroidal Neovascularization Secondary to Causes Other Than Age-Related Macular Degeneration: A Phase I Clinical Trial

Heier, Jeffrey S.; Brown, David M.; Ciulla, Thomas A.; Abraham, Prema; Bankert, Joy M.; Chong, Sandy; Daniel, Paul E.; Kim, Ivana K.

doi:10.1016/j.ophtha.2010.04.016

Cited by 46 publications

(26 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 Recent studies have suggested that the use of intravitreal ranibizumab is efficacious in the treatment of CNV secondary to causes other than AMD, such as pathologic myopia or ocular histoplasmosis. 13,14 Similar reports exist of outcomes of bevacizumab treatment in eyes with CNV secondary to non-AMD causes. 15 The use of intravitreal ranibizumab for the treatment of AS-related CNV has been reported to be more effective when compared with previous reports of laser photocoagulation or PDT, with most eyes demonstrating a stabilisation or improvement in visual acuity.…”

Section: Introductionmentioning

confidence: 63%

Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks

Shah

Amoaku

2012

Eye

View full text Add to dashboard Cite

Aims To assess the medium to long-term efficacy and safety of intravitreal ranibizumab for the treatment of choroidal neovascularisation (CNV) secondary to angioid streaks (AS). Methods A total of 12 eyes of nine patients treated with intravitreal ranibizumab (0.5 mg in 0.05 ml) for CNV secondary to AS were retrospectively identified. Efficacy of treatment was determined by changes in best-corrected LogMAR visual acuity (BCVA) and optical coherence tomography. Changes with respect to baseline BCVA were defined as improved or reduced with a gain or loss of more than 10 letters, respectively, or stable if remaining within 10 letters. Results Over a mean follow-up of 21.75 months (range: 1-54), patients received mean 5.75 (range: 2-15) intravitreal ranibizumab injections per affected eye. BCVA improved in three eyes (25%), stabilised in eight eyes (66.67%), and deteriorated in one eye (8.33%). There was no significant change in central retinal thickness (CRT) over the follow-up period (P ¼ 0.1072). No drug-related systemic side effects were recorded. Conclusion The long-term treatment of CNV secondary to AS with intravitreal ranibizumab showed a stabilisation in CRT and an improvement or stabilisation of BCVA. The absence of systemic side effects was reassuring. Further long-term prospective studies are required to validate these findings.

show abstract

Section: Introductionmentioning

confidence: 63%

Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks

Shah

Amoaku

2012

Eye

View full text Add to dashboard Cite

show abstract

“…[8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] Although the short-term results have demonstrated significant visual improvement following anti-VEGF therapy, the longer term visual outcomes appeared more variable. 14,[26][27][28] In addition, many previous studies have included both treatment naïve cases and previously treated eyes, as well as subfoveal and non-subfoveal CNV in the series, making comparison of results more difficult.…”

Section: Discussionmentioning

confidence: 99%

“…6,7 In the past few years, various studies have demonstrated the short-term efficacy of intravitreal antivascular endothelial growth factor (VEGF) agents in treating myopic CNV, including both bevacizumab [8][9][10][11][12][13][14][15][16][17][18] and ranibizumab. [18][19][20][21][22][23][24][25] Most of the studies have demonstrated significant mean visual improvement after anti-VEGF therapy and the beneficial effects were maintained at 12 months. In addition, several more recent studies have also reported the longer term visual outcomes of up to 2 years following intravitreal bevacizumab treatment for myopic CNV.…”

Section: Introductionmentioning

confidence: 99%

Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization

Lai

Luk

Lee

et al. 2012

Eye

View full text Add to dashboard Cite

“…4 In addition, several clinical studies have showed promising results for a variety of diseases involving CNV. 5,6 In CNV secondary to pathologic myopia, some case series showed significant vision improvement with anti-VEGF drugs. 7 Despite fewer reports than bevacizumab (Avastin, Genentech, South San Francisco, CA), treatment with ranibizumab (Lucentis, Novartis, Basel, Switzerland) in myopic CNV resulted in significant visual improvement.…”

mentioning

confidence: 99%

The 12-Month Outcome of Three Consecutive Monthly Intravitreal Injections of Ranibizumab for Myopic Choroidal Neovascularization

Kung

2012

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Purpose: The aim of this study was to evaluate the 12-month outcomes, efficacy, and safety of three consecutive monthly intravitreal ranibizumab injections for myopic choroidal neovascularization (CNV). Methods: We retrospectively reviewed the medical records of 25 consecutive eyes that received a loading dose of three consecutive monthly intravitreal injections of ranibizumab for myopic CNV between February, 2008, and March, 2010, with a follow-up of 12 months. Eyes with persistent or recurrent CNV after 3 months received additional ranibizumab injections as needed. Patients' demographic data, best corrected visual acuity (BCVA), CNV findings on fluorescent angiography (FAG), central macular thickness (CMT) on optical coherence tomography (OCT), total number of treatments, and complications were recorded. Results: Mean baseline BCVA was 0.73 logarithm of the minimum angle of resolution (logMAR) (standard deviation [SD] 0.63), and improved significantly to 0.42 logMAR (SD 0.43) at 1 month, 0.38 logMAR (SD 0.47) at 2 months, 0.34 logMAR (SD 0.43) at 3 months, and 0.34 logMAR (SD 0.40) at 12 months (all P < 0.001, Wilcoxon signed-rank test). The average number of injections was 3.44 (SD 0.92). At 12 months, mean improvement was 2.88 lines (SD 2.35), and 20 eyes (80%) showed a gain of at least one line after treatment. At 3 months, OCT showed significant reduction in CMT (P = 0.012, two-tailed t-test), and FAG showed significant reduction of mean CNV size from 0.3 (SD 0.16) to 0.19 (SD 0.12) disc area (P = 0.007, two-tailed t-test). No angiographic leakage was evident at 3 months in 21 eyes (84%); four eyes (16%) required additional injections for persistent leakage. Two eyes (8%) had recurrent CNV during follow-up and required retreatment. No complications were noted after treatment. Conclusions: An initial loading dose of three ranibizumab injections is safe and effective in treating myopic CNV, with visual improvement maintained over 12 months.

show abstract

Ranibizumab for Choroidal Neovascularization Secondary to Causes Other Than Age-Related Macular Degeneration: A Phase I Clinical Trial

Cited by 46 publications

References 18 publications

Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks

Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks

Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization

The 12-Month Outcome of Three Consecutive Monthly Intravitreal Injections of Ranibizumab for Myopic Choroidal Neovascularization

Contact Info

Product

Resources

About